GAB1 Rewrites EGFR Condensate Size on Membranes
A new preprint from MIT describes a membrane-based control system for EGFR condensates that is more dynamic than simple receptor clustering. In reconstituted supported lipid bilayers and accompanying simulations, the intrinsically disordered adaptor protein GAB1 did something unexpected: it actively dissolved large EGFR condensates and then re-nucleated smaller assemblies with a different composition. The work places phase separation squarely inside receptor signaling biology, while also showing that the same physical process can be turned on and off by sequence features inside an adaptor protein.
The result matters because EGFR signaling has long been associated with receptor clustering, yet the size of those clusters appears to differ sharply between purified systems and living cells. Phosphorylated EGFR can form micron-scale condensates in vitro, but in cells it is usually organized into smaller nanoscale structures. This study offers a molecular explanation for that gap. GAB1 does not simply join the cluster; it can dismantle one arrangement and build another.
One sentence captures the core finding: GAB1 can disassemble EGFR condensates and replace them with smaller, compositionally distinct assemblies.
An Intrinsically Disordered Region With an Active Role
The most striking part of the model is the role of the intrinsically disordered region in GAB1. Dissolution of EGFR condensates required unphosphorylated tyrosines within that region. Once those tyrosines were phosphorylated, the dissolving activity disappeared. That switch-like behavior points to a direct regulatory logic: the same protein sequence can move between a state that remodels receptor condensates and a state that no longer does so, simply through phosphorylation.
This fits a broader biochemical principle. Intrinsically disordered regions often behave less like rigid scaffolds and more like tunable interaction surfaces, able to sample many weak contacts at once. In a phase-separated signaling environment, those weak contacts can determine whether a condensate grows, shrinks, or reorganizes into a different material state. GAB1 appears to exploit exactly that sort of chemistry. Its unphosphorylated tyrosines are not passive residues waiting for modification; they are part of the mechanism that changes condensate stability.
The study also extends the idea beyond a single adaptor. The authors point out that similar tyrosine-based sequence features occur across hundreds of proteins, including many involved in signal transduction. If those motifs behave similarly in other contexts, protein phosphorylation could be acting not only as a docking code, but also as a way to regulate mesoscale material properties inside signaling complexes.
PH Domain Oligomerization and Lipid Control
After GAB1 dissolves existing EGFR condensates, it helps nucleate a second class of assemblies. Those new structures depended on PH domain-driven oligomerization. Here, membrane composition became part of the regulatory circuit. Phosphoinositide lipids inhibited the oligomerization step, linking local lipid chemistry to receptor organization.
That detail gives the work a more complete membrane story. EGFR signaling does not occur in a vacuum; the receptor sits in a lipid environment that can stabilize or suppress higher-order clustering. By making PH domain activity sensitive to phosphoinositides, the membrane can influence whether GAB1 promotes a compact condensate or blocks that process altogether. This adds a second layer of control after the tyrosine switch, and it helps explain why receptor organization in cells is so tightly constrained.
The physical implication is straightforward. A receptor condensate can be large and stable in one membrane composition, then far more limited in another. GAB1 sits at the center of that rearrangement, converting a broad assembly into a smaller one while membrane lipids constrain the next step.
Why the Size of a Signaling Condensate Matters
Size is not a cosmetic feature of receptor clustering. In signaling pathways, the dimensions and composition of a condensate influence which proteins are concentrated, how long they remain together, and how strongly downstream pathways are engaged. A micron-scale assembly and a nanoscale cluster can produce very different signaling outputs, even if they begin with the same receptor.
This preprint makes that idea more concrete by showing that condensate dissolution and re-nucleation are separable events. GAB1 does not merely cap growth; it appears to remodel the condensate into a different architecture. For a receptor such as EGFR, that kind of control could determine whether signaling remains diffuse, becomes locally amplified, or is quickly terminated.
The mechanism also suggests a reusable principle in cell biology. Phase-separated receptor systems may be governed by modular proteins that do not just scaffold signaling complexes, but actively edit them. In that sense, the adaptor is performing molecular triage: dissolve one assembly, seed another, and let phosphorylation and lipid composition decide which state survives.
A Broader Signaling Code Emerges
The study’s authors extend their interpretation beyond EGFR. An AlphaFold screen identified dozens of additional PH domains predicted to self-associate, raising the possibility that PH domain oligomerization is more common than assumed. If true, membrane-encoded control over receptor organization may be a general feature of signaling pathways rather than an EGFR-specific curiosity.
The same logic applies to the unphosphorylated tyrosines in disordered regions. Their distribution across many proteins suggests that evolution may have repurposed a simple chemical switch into a broad mechanism for controlling condensate size and stability. Phosphorylation would then do more than recruit effector proteins; it would tune the material state of signaling assemblies themselves.
The practical consequence is that receptor reorganization can be reprogrammed through modular protein features. Such a system offers a new framework for thinking about disease pathways driven by aberrant receptor clustering, especially in cancer biology where EGFR signaling is frequently altered. The preprint does not claim a therapeutic advance, and it does not test disease models. It does, however, define a mechanism that future work could eventually exploit to alter receptor organization without directly targeting the receptor alone.
The most important unresolved issue is how these membrane and phosphorylation rules behave in living cells across different signaling contexts. The preprint establishes the mechanism in reconstituted systems and simulations, but the full cellular reach of GAB1-mediated condensate remodeling remains to be mapped.